Celgene : CELG

All CELG Articles

433 Articles

Douglas A. McIntyre | Jul 23, 2009 at 7:47 AM EDT

Top Day Trader Alerts (MEDX, ISRG, OREX, CELG, EBAY, SNDK, PSUN, QCOM)

The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume…

Douglas A. McIntyre | Jun 25, 2009 at 11:31 AM EDT

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early…

Douglas A. McIntyre | May 27, 2009 at 1:34 PM EDT

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data…

Douglas A. McIntyre | Apr 22, 2009 at 6:51 AM EDT

Top Analyst Upgrades (ANDE, CAT, CELG, CLX, DNDN)

It is actually looking pretty thin out there in the land of analyst upgrades. These are the few upgrades and…

Douglas A. McIntyre | Apr 17, 2009 at 2:05 PM EDT

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association…

Douglas A. McIntyre | Feb 18, 2009 at 7:31 AM EST

Top Pre-Market Analyst Upgrades & Downgrades (COF, CELG, ROCK, MOD, SNN, AFL, AMX, SPSS, VQ, WMS)

These are ten of the top pre-market analyst calls for upgrades and downgrades we have seen from Wall Street this…

Douglas A. McIntyre | Feb 5, 2009 at 5:57 PM EST

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know…

Douglas A. McIntyre | Jan 5, 2009 at 7:15 AM EST

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT…

Douglas A. McIntyre | Dec 10, 2008 at 11:04 AM EST

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally…

Douglas A. McIntyre | Oct 13, 2008 at 6:18 AM EDT

Top Pre-Market Analyst Upgrades (ANN, CVC, COF, CELG, GME, PPDI, STJ, STI, THQI, WOOF, WU)

These are some of the many research upgrades we have seen from Wall Street analysts this Monday morning with more…

Douglas A. McIntyre | Aug 13, 2008 at 5:49 AM EDT

24/7 Wall St. Biotech Report: Short-Selling And Splits (AMGN)(CELG)

Short sellers moved out of biotech stocks in the latest period according to Biohealth Investor. The short interest in Amgen…

Douglas A. McIntyre | Jul 4, 2008 at 7:31 AM EDT

This Week’s BioHealth & Biotech Top Stories

We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and…

Douglas A. McIntyre | Jun 14, 2008 at 7:31 AM EDT

The Week’s Top BioHealth Issues For Next Week (PFE, TEVA, CRA, IVGN, CMED, ANPI, ISRG, VVUS, CELG)

One key stock to watch next week is Pfizer Inc. (NYSE: PFE). While it has been in the land of…

Douglas A. McIntyre | Feb 4, 2008 at 2:41 PM EST

Biotech News Day (February 4, 2008) (AMAG, AOB, AMGN, CELG, MNTA, OMRI, SVA, STEM)

Below are some of the top issues affecting biotech shares today: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company developing…

Douglas A. McIntyre | Jan 28, 2008 at 1:43 PM EST

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis. This…

1 … 26 27 28 29

Celgene : CELG

All CELG Articles

Top Day Trader Alerts (MEDX, ISRG, OREX, CELG, EBAY, SNDK, PSUN, QCOM)

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

Top Analyst Upgrades (ANDE, CAT, CELG, CLX, DNDN)

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

Top Pre-Market Analyst Upgrades & Downgrades (COF, CELG, ROCK, MOD, SNN, AFL, AMX, SPSS, VQ, WMS)

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Top Pre-Market Analyst Upgrades (ANN, CVC, COF, CELG, GME, PPDI, STJ, STI, THQI, WOOF, WU)

24/7 Wall St. Biotech Report: Short-Selling And Splits (AMGN)(CELG)

This Week’s BioHealth & Biotech Top Stories

The Week’s Top BioHealth Issues For Next Week (PFE, TEVA, CRA, IVGN, CMED, ANPI, ISRG, VVUS, CELG)

Biotech News Day (February 4, 2008) (AMAG, AOB, AMGN, CELG, MNTA, OMRI, SVA, STEM)

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Celgene : CELG

All CELG Articles

Top Day Trader Alerts (MEDX, ISRG, OREX, CELG, EBAY, SNDK, PSUN, QCOM)

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

Top Analyst Upgrades (ANDE, CAT, CELG, CLX, DNDN)

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

Top Pre-Market Analyst Upgrades & Downgrades (COF, CELG, ROCK, MOD, SNN, AFL, AMX, SPSS, VQ, WMS)

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Top Pre-Market Analyst Upgrades (ANN, CVC, COF, CELG, GME, PPDI, STJ, STI, THQI, WOOF, WU)

24/7 Wall St. Biotech Report: Short-Selling And Splits (AMGN)(CELG)

This Week’s BioHealth & Biotech Top Stories

The Week’s Top BioHealth Issues For Next Week (PFE, TEVA, CRA, IVGN, CMED, ANPI, ISRG, VVUS, CELG)

Biotech News Day (February 4, 2008) (AMAG, AOB, AMGN, CELG, MNTA, OMRI, SVA, STEM)

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do